Profile data is unavailable for this security.
About the company
Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company. The Company is a developer of T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with serious diseases. Its pipeline products include Ebvallo (Tab-cel), ATA3219, and ATA3431. The Company’s T-cell immunotherapy, tab-cel (tabelecleucel), is in Phase III development for patients with EBV-driven post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed rituximab or rituximab plus chemotherapy, as well as other EBV-driven diseases. Its ATA3219 allogeneic CD19 CAR T immunotherapy, targeting B-cell malignancies and autoimmune diseases, is based on a next-generation 1XX CAR co-stimulatory domain and EBV T-cell platform and does not require TCR or HLA gene editing. ATA3431 is an allogeneic, bispecific CAR directed against CD19 and CD20 for B-cell malignancies and autoimmune disease.
- Revenue in USD (TTM)151.93m
- Net income in USD23.40m
- Incorporated2012
- Employees38.00
- LocationAtara Biotherapeutics Inc1280 Rancho Conejo BlvdTHOUSAND OAKS 91320United StatesUSA
- Phone+1 (805) 623-4211
- Fax+1 (302) 636-5454
- Websitehttps://www.atarabio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioqual Inc | 46.54m | 453.25k | 33.55m | 108.00 | 74.02 | 0.938 | 12.22 | 0.7209 | 0.5068 | 0.5068 | 52.03 | 39.99 | 0.7111 | -- | 3.19 | -- | 0.6926 | 4.12 | 0.7745 | 4.83 | 12.85 | 16.15 | 0.974 | 4.03 | -- | -- | 0.00 | 32.81 | -16.60 | 1.06 | -316.79 | -- | -36.99 | -6.51 |
| NextCure Inc | 0.00 | -58.01m | 33.55m | 43.00 | -- | 1.42 | -- | -- | -24.19 | -24.19 | 0.00 | 8.84 | 0.00 | -- | -- | 0.00 | -89.28 | -27.70 | -105.20 | -28.91 | -- | -- | -- | -1,336.59 | -- | -- | 0.00 | -- | -- | -- | 11.27 | -- | -32.45 | -- |
| Cell Source Inc | 0.00 | -6.57m | 34.03m | -- | -- | -- | -- | -- | -0.1613 | -0.1613 | 0.00 | -0.4379 | 0.00 | -- | -- | -- | -2,039.39 | -1,758.85 | -- | -- | -- | -- | -- | -- | -- | -3.74 | -- | -- | -- | -- | -3.55 | -- | -- | -- |
| Outlook Therapeutics Inc | 297.49k | -102.86m | 35.05m | 17.00 | -- | -- | -- | 117.83 | -2.71 | -2.71 | 0.0068 | -0.5971 | 0.0169 | 0.4221 | -- | 17,499.41 | -583.70 | -240.08 | -- | -- | -57.80 | -- | -34,576.16 | -22,354.50 | 0.2795 | -151.67 | -- | -- | -- | -- | 17.17 | -- | -- | -- |
| INmune Bio Inc | 50.00k | -49.89m | 35.36m | 22.00 | -- | 1.39 | -- | 707.17 | -2.14 | -2.14 | 0.0021 | 0.9546 | 0.0012 | -- | 0.0258 | 2,272.73 | -115.83 | -45.54 | -153.59 | -52.16 | -- | -- | -99,774.00 | -19,298.45 | -- | -942.22 | 0.00 | -- | -90.97 | -- | -40.24 | -- | -- | -- |
| Atara Biotherapeutics Inc | 151.93m | 23.40m | 35.40m | 38.00 | 2.24 | -- | 1.33 | 0.233 | 2.19 | 2.19 | 12.81 | -5.08 | 1.76 | 3.99 | 93.55 | 993,006.60 | 27.07 | -67.79 | -- | -93.07 | 81.63 | -- | 15.40 | -558.47 | 1.02 | 15.24 | 8.31 | -- | 1,404.02 | -- | 69.07 | -- | -46.73 | -- |
| Actinium Pharmaceuticals Inc | 90.00k | -34.60m | 35.56m | 37.00 | -- | 2.58 | -- | 395.15 | -1.11 | -1.11 | 0.0029 | 0.4419 | 0.0013 | -- | -- | 2,432.43 | -50.05 | -43.20 | -55.95 | -47.84 | -- | -- | -38,443.33 | -7,408.74 | -- | -- | 0.0009 | -- | -100.00 | -- | 21.66 | -- | -29.66 | -- |
| CervoMed Inc | 6.16m | -25.58m | 35.99m | 15.00 | -- | 1.38 | -- | 5.84 | -2.87 | -2.87 | 0.6919 | 2.81 | 0.155 | -- | 7.58 | 410,652.00 | -64.37 | -54.89 | -71.42 | -60.99 | -- | -- | -415.36 | -428.45 | -- | -- | 0.00 | -- | 36.29 | -- | -650.08 | -- | -- | -- |
| PDS Biotechnology Corp | 0.00 | -34.88m | 36.24m | 24.00 | -- | 3.49 | -- | -- | -0.8194 | -0.8194 | 0.00 | 0.1982 | 0.00 | -- | -- | 0.00 | -80.05 | -57.93 | -125.74 | -68.38 | -- | -- | -- | -- | -- | -8.43 | 0.6552 | -- | -- | -- | 12.42 | -- | -- | -- |
| Xilio Therapeutics Inc | 31.80m | -58.49m | 36.53m | 64.00 | -- | -- | -- | 1.15 | -0.6571 | -0.6571 | 0.3348 | -0.1562 | 0.3053 | -- | -- | 496,937.50 | -56.14 | -67.88 | -102.68 | -81.71 | -- | -- | -183.90 | -5,578.28 | -- | -2.84 | -- | -- | -- | -- | 23.77 | -- | -45.00 | -- |
| Cypherpunk Technologies Inc | 0.00 | -50.81m | 36.86m | 52.00 | -- | 10.01 | -- | -- | -1.23 | -1.23 | 0.00 | 0.065 | 0.00 | -- | -- | 0.00 | -132.94 | -79.03 | -196.76 | -93.29 | -- | -- | -- | -9,055.53 | -- | -- | 0.00 | -- | -- | -- | 16.74 | -- | -- | -- |
| Tvardi Therapeutics Inc | 4.02m | -13.95m | 37.15m | 10.00 | -- | 1.33 | -- | 9.23 | -8.36 | -8.36 | 0.7709 | 2.97 | 0.0891 | -- | -- | 402,400.00 | -30.87 | -36.79 | -40.26 | -41.45 | 100.00 | -- | -346.55 | -155.60 | -- | -- | 0.00 | -- | -65.96 | -18.53 | 40.20 | -- | 125.35 | -- |
| Sensei Biotherapeutics Inc | 0.00 | -24.14m | 37.60m | 14.00 | -- | 1.63 | -- | -- | -19.16 | -19.16 | 0.00 | 18.24 | 0.00 | -- | -- | 0.00 | -59.72 | -43.45 | -68.03 | -48.13 | -- | -- | -- | -- | -- | -- | 0.0083 | -- | -- | -- | 11.57 | -- | 22.47 | -- |
| Jasper Therapeutics Inc | 0.00 | -91.02m | 37.78m | 64.00 | -- | 3.26 | -- | -- | -5.90 | -5.90 | 0.00 | 0.4135 | 0.00 | -- | -- | 0.00 | -116.04 | -75.11 | -147.54 | -86.11 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -10.55 | -- | -- | -- |
| ABVC Biopharma Inc | 797.92k | -4.12m | 38.19m | 16.00 | -- | 2.97 | -- | 47.86 | -0.2223 | -0.2223 | 0.0464 | 0.4985 | 0.0448 | -- | 0.408 | 49,870.00 | -24.89 | -105.17 | -42.73 | -217.00 | 0.2469 | 75.19 | -555.90 | -2,124.21 | 0.6241 | -13.71 | 0.0662 | -- | 234.31 | -6.20 | 37.05 | -- | -- | -- |
Data as of Mar 03 2026. Currency figures normalised to Atara Biotherapeutics Inc's reporting currency: US Dollar USD
23.89%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| EcoR1 Capital, LLCas of 31 Dec 2025 | 573.18k | 7.95% |
| Redmile Group LLCas of 31 Dec 2025 | 441.70k | 6.13% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 190.86k | 2.65% |
| Marshall Wace LLPas of 31 Dec 2025 | 148.63k | 2.06% |
| GlobeFlex Capital LPas of 31 Dec 2025 | 77.22k | 1.07% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 65.80k | 0.91% |
| Geode Capital Management LLCas of 31 Dec 2025 | 62.38k | 0.87% |
| Mackenzie Financial Corp.as of 31 Dec 2025 | 58.67k | 0.81% |
| Acadian Asset Management LLCas of 31 Dec 2025 | 54.05k | 0.75% |
| Staley Capital Advisers, Inc.as of 31 Dec 2025 | 50.00k | 0.69% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
